Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Friday, September 19, 2025
Minovia Therapeutics Ltd, a clinical-stage biotechnology company focused on therapies for mitochondrial diseases and age-related decline, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its lead investigational compound, MNV-201, in Myelodysplastic Syndrome (MDS). MDS is a serious age-related blood disorder that affects the bone marrow.
This new designation adds to the FDA Fast Track and Rare Paediatric Disease Designations already granted to MNV-201 for Pearson Syndrome, an ultra-rare and life-threatening mitochondrial condition in children. Minovia is currently running a Phase 2 clinical trial in Pearson Syndrome.
The FDA’s Fast Track Designation is intended to speed up the development and review of treatments for serious or life-threatening conditions where current options are limited. Benefits of this status include more frequent engagement with the FDA, the possibility of priority review, and the option of a rolling submission of a future Biologics Licence Application (BLA) for MNV-201.
In addition, Minovia recently entered into a business combination agreement with Launch One Acquisition Corp., a Nasdaq-listed special purpose acquisition company. The transaction is expected to close in late 2025, after which the combined entity will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.
Source: globenewswire.com
